Ahammune Biosciences Raises $5 Million in Series A Funding to Advance Vitiligo Treatment

Pune-based biotech startup Ahammune Biosciences has successfully raised $5 million in a Series A funding round led by Pi Ventures. Other key investors include Capital2B, Colossa Ventures, Bipin Agarwal, Unicornus Maximus LLP, and existing backers Ideaspring Capital, Kotak Alternate Assets, Legacy Assets LLP, and IAN.

This fresh investment round will be pivotal for Ahammune as the company continues to expand its patent portfolio and conducts Phase II human clinical trials for its vitiligo treatment candidate. The funding will fuel the startup’s ongoing research and development efforts on additional immune-mediated skin diseases.

Previously, Ahammune had raised nearly $3 million from existing investors and external parties. With this new funding, the company is gearing up to progress significantly in its novel vitiligo treatment program. The startup’s innovative small-molecule therapeutic candidate aims to pigment the skin and stimulate the activity of colour-producing cells without causing systemic immunosuppression.

About Ahammune Biosciences

Parul Ganju and Krishnamurthy Natarajan co-founded Ahammune Biosciences in 2016. The clinical-stage pharmaceutical company is focused on developing breakthrough therapies for skin disorders. Its mission is to address unmet medical needs for vitiligo and other immune-related skin illnesses.

This funding round marks a significant milestone for the biotech firm, which is positioning itself at the forefront of dermatology and immune-modulation research.